Welcome to our dedicated page for Electrocore SEC filings (Ticker: ECOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to electroCore, Inc. (Nasdaq: ECOR) SEC filings, offering a detailed view of how the company reports its activities as a commercial-stage bioelectronic medicine and wellness business. electroCore focuses on non-invasive neuromodulation and bioelectronic technologies, including its gammaCore nVNS and Quell neurostimulator prescription products and its Truvaga and TAC-STIM wellness and performance devices.
Through forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q, investors can review discussions of electroCore’s business, risk factors, financial condition, and operating results. Current reports on Form 8-K, several of which are referenced in the input data, disclose material events including quarterly financial results, private placements of common stock to satisfy specific obligations, and changes in the composition and leadership of the board of directors.
Other filings may cover topics such as stockholder votes on charter amendments, advisory votes on executive compensation, and the appointment of new independent directors or committee members. Together, these documents outline electroCore’s governance practices, capital structure developments, and key financial metrics over time.
On Stock Titan, these SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the contents of lengthy reports, highlight important sections of 10-K and 10-Q filings, and clarify the implications of Form 8-K disclosures. Users can also review insider-related filings such as Form 4, where available, to see reported transactions by directors and officers. This combination of primary documents and AI-generated insights is intended to make electroCore’s regulatory record more accessible to a wide range of readers.
Form 144 filing reports proposed dispositions of Common Stock linked to Charles Schwab Corp. The filing lists 10,000 shares described under "Securities To Be Sold" dated 08/04/2024 as "Compensation For Position of CEO." The excerpt also shows a prior sale of 16,072 shares on 04/10/2026 for $96,753.44 by Daniel Goldberger. The filing lists the issuer address and NASDAQ as the market.
electroCore, Inc. Chief Operating Officer Michael Fox received an equity award of 70,000 shares of common stock, reported as an acquisition at $0.00 per share. Following this grant, he directly holds 70,000 shares.
The award is structured as restricted stock units that vest over three years: one-third on the first anniversary of the grant date and the remaining two-thirds in equal annual installments over the next two years. Vesting requires continued service, with additional protection if his employment ends without “cause” or for “good reason” within two years after a “change in control” under the company’s Executive Severance Policy.
electroCore, Inc. former officer and director Daniel S. Goldberger reported an open-market sale of 16,072 shares of common stock at $6.02 per share. According to the footnotes, the shares were sold solely to cover tax withholding obligations triggered by the vesting and settlement of previously issued RSUs.
After the transaction, Goldberger directly owns 291,471 shares, which include 3,665 newly vested shares and 43,200 RSUs that continue to vest in equal monthly installments of 3,600 RSUs, subject to ongoing consulting under a separation agreement. The filing notes a Section 16(b) claim of $1,182, which he voluntarily paid to electroCore.
electroCore, Inc. Chief Operating Officer Michael Fox has filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting person at the company but does not report any stock transactions or specific holdings in the available data.
Lev Joshua S. reported acquisition or exercise transactions in this Form 4 filing.
electroCore, Inc. reported a new equity award to its CFO and Interim President, Joshua S. Lev. He received 45,000 shares of Common Stock as a grant of Restricted Stock Units (RSUs) that vest in full on December 31, 2026, if he remains in continuous service or meets specified change in control conditions. After this grant, he holds 94,556 shares of Common Stock, including 12,556 shares and 82,000 shares underlying RSUs scheduled to vest between 2026 and 2029, reflecting primarily compensation-based, not open-market, activity.
electroCore, Inc. director Thomas J. Errico exercised warrants to acquire a total of 42,055 shares of common stock, with 22,803 shares exercised at an exercise price of $4.35 per share and 19,252 shares at $6.43 per share.
Following these exercises, his directly owned common stock is reported at 350,071 shares. A footnote explains this includes 259,106 shares owned directly, 1,296 shares held by a family trust, 11,000 shares held by a trust for his benefit, 26,615 unvested shares underlying deferred stock units, and 52,054 shares that have vested from prior deferred stock units.
electroCore, Inc. is a bioelectronic technology company focused on non-invasive neuromodulation devices and wellness products. Its main commercial offerings are the prescription gammaCore vagus nerve stimulation system for primary headaches and Quell Fibromyalgia for chronic pain, plus Truvaga and TAC-STIM wellness devices.
The company relies heavily on government and health-system customers: U.S. Department of Veterans Affairs facilities generated 71.2% of 2025 revenue, and U.K. NHS sales under the MedTech Funding Mandate added 4.4%. As of March 13, 2026, 8,083,558 common shares were outstanding and the June 30, 2025 non‑affiliate equity market value was $27,950,688.
electroCore highlights the need for additional capital, concentration of revenue in a few large customers, ecommerce and pricing risks, regulatory and reimbursement uncertainty in the U.S. and U.K., cybersecurity and FTC compliance exposure, a material weakness in internal controls, and Nasdaq listing and debt covenant risks.
electroCore, Inc. reported strong top-line growth for 2025 while remaining loss-making and announced key leadership changes. Net sales for the year ended December 31, 2025 rose to $32.0 million, up about 27% from 2024, driven by 25% growth in U.S. prescription revenue and a 97% increase in general wellness sales. Gross profit increased to $27.8 million with gross margin improving to 87% from 85%.
Operating expenses rose to $40.9 million, reflecting higher sales and marketing and additional legal, IT, and bad debt costs. GAAP net loss widened to $14.0 million, or $1.65 per share, while adjusted EBITDA net loss improved slightly to $8.7 million. Total cash, cash equivalents, and marketable securities were $11.6 million at year-end and stockholders’ equity showed a deficit of $1.7 million. For 2026, the company guides to roughly 30% annual revenue growth. CEO Dan Goldberger will retire effective April 1, 2026, with CFO Joshua Lev becoming interim President and Michael Fox joining as Chief Operating Officer.
electroCore, Inc. Chief Financial Officer Lev Joshua S. reported new equity awards in the company’s common stock. On January 26, 2026, he acquired 2,889 shares at a price of $0 and a separate 25,000-share award, both held directly.
The 25,000-share award represents restricted stock units that vest in three equal 33% installments on each of the first, second, and third anniversaries of the grant date, subject to continued service. Unvested portions can also vest if he is terminated without cause or resigns for good reason within two years after a change in control, under the company’s Executive Severance Policy. His reported beneficial ownership after these transactions is 49,556 shares, including 21,667 shares tied to previously granted restricted stock units with vesting dates in 2027 and 2028.
electroCore CEO Daniel S. Goldberger reported new equity awards in the company. On January 26, 2026, he acquired 20,375 shares of electroCore common stock at $7.47 per share and received a grant of 26,000 restricted stock units at no cost.
The new restricted stock units vest in three equal installments on the first, second, and third anniversaries of the grant date, subject to continued service, and may also vest upon certain qualifying termination events following a change in control. After these transactions, Goldberger beneficially owned 338,940 shares of electroCore common stock, including shares underlying previously granted restricted stock units with future vesting dates.